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in Poland, the reduction in mortality from cor‑
onary heart disease (CHD) could be mostly ex‑
plained by favorable changes in CVD risk factors 
but the most recent observations in the general 
INTRODUCTION Prevention is the most effi‑
cient and economically justified method to re‑
duce cardiovascular disease (CVD) morbidity 
and mortality.1 Earlier estimates suggested that 
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ABSTRACT
BACKGROUND The EUROACTION study (nurse ‑coordinated multidisciplinary, family ‑based cardiovascular 
disease prevention program) documented the efficacy of a nurse ‑managed, comprehensive prevention 
program in reducing risk factors for cardiovascular disease (CVD). No information was available on survival.
AIMS The aim of the study was to assess the effects of EUROACTION intervention on CVD risk factors 
and 12‑year survival in the Polish component of the study.
METHODS Two district hospitals and 2 primary care practices were allocated randomly to intervention 
(INT) or usual care (UC). The primary endpoints were lifestyle and risk factors changes at 1‑year follow‑
up. Differences in survival were analyzed using the multivariable Cox proportional hazards regression 
models.
RESULTS The study involved 628 patients with coronary heart disease (CHD) and 711 high ‑risk patients. 
Compared to UC, INT patients achieved healthier lifestyles and a larger reduction of risk factors at 1 year 
but these differences were not maintained 12 years after the intervention. Less deaths occurred in patients 
from the INT hospital and from INT primary practice (hazard ratio [HR], 0.58; 95% CI, 0.42–0.82 and HR, 
0.53; 95% CI, 0.3–0.95, respectively). Adjustment for the covariates slightly attenuated the estimates and 
removed significance (HR, 0.74; 95% CI, 0.52–1.04 and HR, 0.66; 95% CI, 0.36–1.24, respectively). For 
combined CHD and high‑risk patient groups, compared with UC, INT patients had a 36% lower risk of 
death after adjustment for age, sex, and history of CHD (HR, 0.64; 95% CI, 0.48–0.86).
CONCLUSIONS The impact of the EUROACTION intervention on lifestyle and CVD risk factors could have 
contributed to lower mortality in INT coronary and high ‑risk patients. These results emphasize the need 
for sustaining the interventions to help patients maintain a healthy lifestyle.
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high ‑risk patients within primary care.1 One 
model of an effective prevention program was 
developed in the international EUROACTION 
study (nurse ‑coordinated multidisciplinary, 
family ‑based cardiovascular disease prevention 
program). It was shown that this ambulatory 
program increased the proportions of patients 
and their families who achieve the goals for CVD 
prevention in terms of lifestyle, risk factors con‑
trol, and use of cardioprotective medications.12
The aim of the present paper was to describe 
the effects of the EUROACTION intervention 
on risk factors in a Polish sample who partici‑
pated in the study, and to investigate whether 
the program which improved standards of pre‑
ventive care in routine clinical practice could 
have an impact on the longitudinal survival in 
patients with CHD and high ‑risk individuals and 
whether the survivors maintain positive life‑
style changes and risk factors control long term.
METHODS The  design and methods used 
in the  EUROACTION project (trial regis‑
tered in the ISRCTN registry of clinical trials, 
ISRCTN71715857), with special attention to 
the details of the intervention program were 
described earlier.12 Below is a brief description 
relevant to the present study and to the specif‑
ic aspects of the Polish component of the study.
The EUROACTION was a matched, cluster‑
‑randomized, controlled trial in 8 European 
countries, 6 pairs of hospitals and 6 pairs of 
primary practices were assigned to an interven‑
tion program (INT) or usual care (UC) for pa‑
tients with CHD or those at high risk of devel‑
oping CVD. This report is focused on the Polish 
component of the study which involved 2 dis‑
trict hospitals (Chrzanów and Olkusz) and 2 pri‑
mary practices from Kraków. In hospitals, pa‑
tients aged 80 years or younger who were hos‑
pitalized due to myocardial infarction or unsta‑
ble or stabile angina were recruited. In general 
practices, patients aged from 50 to 79 years, who 
were free of CVD, who were on treatment with 
antihypertensive or lipid ‑lowering drugs start‑
ed in the year prior to the recruitment or were 
diagnosed with diabetes mellitus within the 3 
years prior the recruitment or at high risk of 
CVD death (SCORE [Systematic Coronary Risk 
Estimation] ≥5% either at the time of recruit‑
ment or projected to age 60 years) and not on 
any treatment, were recruited.
Hospitals and primary practices were central‑
ly randomly allocated to INT or UC. In the INT 
hospitals and primary practices, after base‑
line assessment of lifestyle, risk factors, and 
drug treatment, patients and their partners 
were invited to attend a structured interven‑
tion program, which consisted of 8 group work‑
shops and a supervised exercise class in hos‑
pitals and 3 workshops followed by individual 
population and in patients with CHD indicate 
that there is still great potential to reduce CVD 
incidence and mortality by lifestyle interven‑
tion, risk factor management, and cardiopro‑
tective medication. Two ‑thirds of Polish gener‑
al adult population have hypercholesterolemia 
(61% are unaware and only 6% controlled), 40% 
of the adult population have hypertension (41% 
not aware and only 23% controlled), and 33% of 
men and 24% of women smoke cigarettes.2-4 Fur‑
ther, risk factors accumulate in the same persons 
and socially disprivileged groups receive less in‑
tensive care5,6 and primary care does not provide 
sufficient counselling on risk factors and life‑
style.7 Results of the Polish component of the EU‑
ROASPIRE (European Action on Secondary and 
Primary prevention through Intervention to Re‑
duce Events) study showed that, despite signifi‑
cant improvements in the use of cardioprotective 
drugs, mainly an increase in the use of statins 
and blood pressure lowering agents in patients 
with CHD, control of risk factors is still not suffi‑
cient. Only one ‑third of patients with CHD with 
hypercholesterolemia and 40% of patients with 
hypertension achieve the treatment goals and 
no considerable change was observed in smok‑
ing, diet, and physical activity for over 15 years.8 
It is obvious that lifestyle modification requires 
well ‑organized and well ‑managed, structured 
prevention and rehabilitation program which 
would be applied to all in need, but in partic‑
ular to patients with CHD and persons at high 
risk. Regrettably, there is evidence that only one‑
third of Polish patients with CHD who were hos‑
pitalized due to the acute manifestation of CHD 
are offered the opportunity to participate in re‑
habilitation programs. This proportion has re‑
mained unchanged for over 15 years and is one of 
the worst among the 24 centers who participated 
in the EUROASPIRE IV study.9 Further, the na‑
tional prevention program funded by the Polish 
National Health Fund (Narodowy Fundusz Zd‑
rowia) which was directed to primary care prac‑
tices, appeared to be not accepted broadly and not 
effective in the control of risk factors.10
Since 2012, the European guidelines for CVD 
prevention recommend the integration of nurse–
co ordinated prevention programs into health‑
care system11 and nurses together with gener‑
al practitioners and allied health professionals 
should deliver CVD prevention programs for 
WHAT’S NEW?
This is the first study showing the reduction of mortality (by around 36%) in 
relation to improvement in the lifestyle and reduction of risk factors achieved 
by a structured, comprehensive, primary and secondary prevention  program, 
the EUROACTION study (nurse ‑coordinated multidisciplinary, family ‑based 
cardiovascular disease prevention program). Further, the study documented 
that with no sustained interventions, favorable lifestyle and risk factors changes 
disappear in longitudinal observation.
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the procedures at the clinic including separation 
and freezing of plasma samples followed the orig‑
inal EUROACTION protocol. Biochemical analy‑
ses were carried out in the laboratory of the Uni‑
versity Hospital in Kraków which is covered by 
the international quality control program.
Statistical analysis Results of the lifestyle, 
risk factors, and cardioprotective treatments 
assessment were presented as means (SD) or as 
numbers and percentages. The differences were 
tested using the χ2 and the t test or the Mann–
Whitney test. The survival analysis was based on 
intention to treat. Differences in survival were 
presented by Kaplan ‑Meier curves and tested by 
the log ‑rank test. Then, they were analyzed using 
the multivariable Cox proportional hazards re‑
gression model. Testing for the proportionality 
assumption of Cox regression was performed for 
each covariate and globally using a formal sig‑
nificance test based on the unscaled and scaled 
Schoenfeld residuals.13 The analyses were con‑
ducted using the STATA, version 14.2 (Stata‑
Corp LP, College Station, Texas, United States).
The study was approved by the bioethics com‑
mittee of Jagiellonian University Medical College.
RESULTS In the Polish arm of the EUROAC‑
TION study, there were 331 eligible patients 
with CHD identified in the INT hospital and 
297 patients with CHD in the UC hospital. Pa‑
tients from the INT and UC hospitals had sim‑
ilar mean age, but there were more women in 
the INT hospital. At recruitment, the proportion 
of patients with clinical diagnosis of myocardial 
consultations in primary practices. Nurses mon‑
itored risk factors and adherence to drug treat‑
ments at each session and reported their ob‑
servations to the doctors who could initiate or 
change the dose of cardioprotective medication. 
Additionally, printed leaflets on risk factors and 
a personal record card for lifestyle and risk fac‑
tor targets were handed out to patients and their 
families were supplied with family support packs.
The primary endpoints were lifestyle change, 
management of blood pressure, lipids, and blood 
glucose to target concentrations, and prescrip‑
tion of cardioprotective drugs measured at 1 
year and assessed by intention to treat.12 Fur‑
ther, all eligible patients and their partners in 
the INT hospital were invited for reassessment 
at 16 weeks. In the UC hospital and primary prac‑
tice, a random subsamples of eligible patients 
had baseline assessment and in the UC hospi‑
tal a random sub sample had an assessment af‑
ter 16 weeks. According to the original EUROAC‑
TION protocol, assessment after 16 weeks was 
not done in primary practices. The study used 
highly standardized methods and participating 
centers were subjected to central quality control 
measures. Frozen blood samples were used in 
biochemical analysis in one central laboratory.12
Follow ‑up observation after at least over 10 
years was attempted only for the Polish sam‑
ple. Survival status was assessed from the res‑
idential registry and by personal contacts with 
participants or their relatives. Participants 
were interviewed during at ‑home visits accord‑
ing to the same questionnaire as at 1‑year as‑
sessment and invited for a visit to the clinic for 
physical examination and blood collection. All 
TABLE 1 Baseline characteristics of the intervention and usual care patients
Hospitals Primary care
INT (n = 331) UC (n = 297) P value INT (n = 325) UC (n = 386) P value
Age, y, mean (SD) 58 (9.91) 59.2 (9.31) 0.12 56.1 (6.25) 58.2 (7.15) <0.001
Sex, n (%) Male 176 (53.2) 185 (62.3) 0.02 138 (42.5) 167 (43.3) 0.83
Female 155 (46.8) 112 (37.7) 187 (57.5) 219 (56.7)
Diagnostic category 
at recruitment, n (%)
Myocardial infarction 93 (28.1) 129 (44.2) <0.001 – – –
Unstable angina 35 (10.6) 32 (11) – –
Stable angina 203 (61.3) 131 (44.8) – –
Risk factors 
at recruitment, n (%)
Smoking – – – 137 (42.3) 92 (24.2) <0.001
Hypertension – – – 228 (68.5) 225 (57.7) 0.01
Dyslipidemia – – – 265 (79.6) 256 (65.6) <0.001
Diabetes – – – 38 (11.4) 120 (30.8) <0.001
Time of observation, y, mean (SD) 12.1 (2.79) 11.6 (3.78) 0.09 12.6 (1.4) 12.1 (2.49) 0.01
Person years, n 3992 3440 <0.001 3480 3870 <0.001
Deaths, n 61 92 <0.001 25 51 0.02
Abbreviations: INT, intervention; UC, usual care
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At 1‑year follow ‑up, compared with UC pa‑
tients, patients from the INT hospital were more 
active, had higher high ‑density lipoprotein cho‑
lesterol (HDL ‑C) levels and were leaner. Howev‑
er, the baseline difference in the level of anxi‑
ety reappeared. No significant differences be‑
tween the UC and INT hospitals were found in 
smoking rates, blood pressure, BMI, consump‑
tion of antiplatelet agents, and the use of ACE‑
‑inhibitors and statins.
The 12‑year survivors among patients from 
the INT hospital did not maintain the favorable 
physically active lifestyle but consumed recom‑
mended amounts of fresh fruit and vegetables 
more frequently and were less anxious. Howev‑
er, they had higher mean total cholesterol and 
LDL ‑C compared with UC patients. No signifi‑
cant differences were found in smoking rates, 
blood pressure, parameters of obesity, and oth‑
er assessed parameters.
High ‑risk primary care patients At baseline, 
the important difference was that compared 
with UC, patients from INT practice smoked 
more frequently, had higher mean blood total 
cholesterol and LDL ‑C but also slightly higher 
HDL ‑C, presented higher levels of anxiety and 
depression and were taking antiplatelet agents 
less frequently. No differences were found in 
blood pressure, BMI, or waist circumference, 
characteristics of diet and use of angiotensin‑
‑converting enzyme (ACE) inhibitors or statins.
At the 1‑year follow‑up, compared with UC 
patients, patients from the INT practice were 
more active, more likely to consume favorable 
amounts of fruit and vegetables more frequent‑
ly, and had lower mean systolic and diastolic 
blood pressure. The differences in total choles‑
terol and LDL ‑C, which were unfavorable for 
patients from the INT practice at the initial as‑
sessment, disappeared. However, the favorable 
difference in the mean HDL ‑C was also not sig‑
nificant and patients from the INT practice had 
higher levels of anxiety and depression. Smok‑
ing rates decreased in both practices but prev‑
alence of smoking remained higher in the INT 
practice. Patients from UC used ACE ‑inhibitors 
less frequently. No significant differences be‑
tween the UC and INT practices were found in 
BMI or waist circumference, and consumption 
of antiplatelet agents or statins.
The 12‑year survivors among patients from 
the INT primary practice did not maintain most 
of the favorable lifestyle and risk factors char‑
acteristics as compared with UC care patients 
with an exception of more frequent consump‑
tion of fruit and vegetables.
Mortality For patients with CHD, the mean 
time of follow ‑up was slightly shorter in the UC 
hospital as compared with the INT hospital 
(11.6 vs 12.1 years) but the difference was not 
infarction was higher in UC patients (TABLE 1). Out 
of the identified patients, 199 in the INT hos‑
pital and 56 in the UC hospital (random sam‑
ple) underwent the initial assessment, and 169 
and 38 respectively (random sample) partici‑
pated in the assessment after 16 weeks. A total 
of 198 patients in the INT hospital and 191 in 
the UC hospital participated in the 1‑year fol‑
low‑up, which was addressed to all patients iden‑
tified. A total of 100 patients in the INT hospi‑
tal and 71 in the UC hospital participated in the 
12‑year follow‑up.
In the primary practices, 325 eligible high ‑risk 
patients were identified in the INT practice and 
386 in the UC practice. There was no difference 
in the proportion of women, but patients from 
the INT practice were slightly younger and were 
exposed more frequently to smoking, hypercho‑
lesterolemia, and hypertension, and less often 
to diabetes as compared with UC practice (TABLE 1). 
Out of the identified high ‑risk patients, 256 un‑
derwent the initial assessment in the INT prac‑
tice and 44 (random sample) in the UC practice; 
234 and 160 respectively participated in the as‑
sessment after 1 year (addressed to all patients 
identified). A total of 149 patients in the INT 
practice and 81 in the UC practice participated 
in the 12‑year follow‑up.
Exposure to risk factors at baseline visit and 
subsequent follow ‑up (after 16 weeks in the case 
of hospitals, 1 year, and 12 years) for INT and 
UC hospitals and primary practices are present‑
ed in TABLE 2.
Patients with coronary heart disease 
At baseline, the important difference was that, 
compared with UC, patients from INT hospital 
were less active, had higher mean blood total 
cholesterol, presented higher level of anxiety and 
depression, and were taking antiplatelet agents 
less frequently. Small difference in favor of INT 
patients was found in waist circumference. No 
differences were found in smoking rates, blood 
pressure, body mass index (BMI), characteris‑
tics of diet and use of ACE ‑inhibitors and statins.
On completion of the intervention program 
(16‑week assessment), the most striking changes 
were observed in physical activity which resulted 
in over 3‑fold more frequent recommended phys‑
ical activity levels in patients from the INT hospi‑
tal. INT patients also reported more frequent con‑
sumption of recommended amounts of oily fish 
and fresh vegetables compared with UC patients. 
Also, there was a decrease in low ‑density lipopro‑
tein cholesterol (LDL ‑C) levels in patients from 
the INT hospital and in consequence, the base‑
line difference between them and patients from 
the UC hospital reversed. At 16‑week follow ‑up, 
the differences in anxiety and depression as well 
as in the use of antiplatelet agents which were 
observed at the initial assessment were no lon‑
ger significant.
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TABLE 2 Cardiovascular disease risk factors in intervention and usual care hospitals and primary care practices
Hospitals Primary care
Baseline 16‑week follow‑up 1‑year follow‑up 12‑year follow‑up Baseline 1‑year follow‑up 12‑year follow‑up
INT 
(n = 199)
UC 
(n = 56)
INT 
(n = 169)
UC  
(n = 38)
INT 
(n = 198)
UC 
(n = 191)
INT 
(n = 100)
UC  
(n = 71)
INT 
(n = 256)
UC  
(n = 44)
INT 
(n = 234)
UC 
(n = 160)
INT 
(n = 149)
UC 
(n = 81)
Current smoker, % 14.6 14.3 21.9 21.1 19.7 25.1 17 21.1 45.7 25a 38.5 18.8c 21.5 14.8
Diet Oily fish ≥3 times 
a week, %
4 3.6 19.5 5.3a 18.1 0b 4 5.6 2 4.6 4.3 4.4 2.7 0
Fruit and 
vegetables ≥400 g 
per day, %
35.2 42.4 63.3 33.3c 56.4 48.2 72 14.1c 49.2 45.5 77.8 39.4c 37.6 19.8b
Physical activity ≥30 min,  
≥4 times a week, %
13.5 46.4c 63.3 18.4c 38.2 24.6b 33 32.4 34.4 29.6 66.2 5.6c 17.7 13
BMI, kg/m², mean (SD) 29.3 (4.01) 29 (3.85) 29.3 (4.16) 29.5 (3.61) 28.9 (4.23) 29.1 (4.65) 30.3 (4.81) 29.4 (4.04) 28.2 (5.07) 28.3 (4.61) 27.8 (4.79) 27.5 (4.56) 28.9 (4.89) 28.2 (4)
Waist circumference, cm, mean (SD) 97 (11.4) 101 (9.5)a 96 (11.9) 102 (9.66)b 95 (11.6) 100 (11.3)c 104 (12.6) 102 (12.8) 93 (12.6) 92 (11.3) 92 (11.9) 90 (14.1) 99 (13.8) 96 (11.3)
SBP, mm Hg, mean (SD) 138 (20.9) 138 (16.6) 139 (19) 141 (13.7) 141 (21.4) 144 (20.4) 140 (21.9) 144 (22.7) 140 (17.3) 141 (15.5) 130 (11.9) 137 (16.7)c 131 (15.3) 132 (15.7)
DBP, mm Hg, mean (SD) 84 (10.7) 85 (10.5) 84 (10.3) 83 (7.3) 84 (11.2) 85 (11.2) 86 (13) 84 (15.7) 85 (8.4) 87 (5.8) 80 (6.9) 85 (8.3)c 81 (9.3) 80 (9.3)
Total cholesterol, mmol/l, mean (SD) 5.23 (1.21) 4.69 (0.87)b 5.22 (1.28) 5.19 (1.14) 5.36 (1.23) 5.42 (1.41) 5 (1.24) 4.41 (1.34)a 6.04 (0.97) 5.54 (1.01)c 5.71 (0.93) 5.55 (0.99) 4.84 (1.25) 4.83 (1.11)
LDL ‑C, mmol/l, mean (SD) 3.23 (1.03) 2.99 (0.71) 2.78 (0.86) 4.28 (1.5)c 3.47 (1.25) 3.57 (1.41) 2.9 (1.05) 2.45 (1.08)a 3.74 (0.91) 3.39 (0.93)a 3.63 (0.93) 3.47 (3.33) 2.54 (1.11) 2.68 (0.96)
HDL ‑C, mmol/l, mean (SD) 1.26 (0.4) 1.15 (0.25) 1.35 (0.36) 1.26 (0.31) 1.46 (0.45) 1.34 (0.42)a 1.35 (0.36) 1.23 (0.4) 1.56 (0.39) 1.43 (0.36)a 1.35 (0.26) 1.39 (0.27) 1.63 (0.72) 1.49 (0.37)
Anxiety (HADS), n, mean (SD) 9.4 (4.25) 7.9 (4.25)a 8.3 (3.76) 7 (3.58) 7.5 (4.18) 6.2 (3.97)b 11.6 (2.29) 12.6 (2.73)a 7.9 (3.89) 4.2 (3.99)c 7.1 (3.69) 5.4 (3.96)c 13 (2.17) 12.7 (2.14)
Depression (HADS), n, mean (SD) 7.7 (3.58) 6.3 (4.07)a 6.9 (3.27) 6.1 (3.68) 5.8 (3.69) 4.9 (3.66) 9.2 (2.17) 9.1 (2.02) 6.3 (3.37) 3.4 (4.33)c 5.9 (3.26) 4.9 (3.42)b 9.1 (1.75) 8.8 (1.86)
Cardioprotective 
drugs
Antiplatelet drugs, % 88.4 98.2a 92.2 97.3 89 91.3 49 53.5 8.6 18.2a 17.5 17.4 17.5 28.4
ACEIs, % 68.2 55.4 68.9 56.8 69.5 74.3 48.4 30.8a 0 0 65.5 52a 38 41.3
Statins, % 65.2 76.8 74.9 83.8 71.1 69.1 54.8 55.4 20.7 22.7 45.9 34.7 44.2 50.7
a P <0.05   
b P <0.01   
c P <0.001
Abbreviations: ACEIs, angiotensin ‑converting enzyme inhibitors; BMI, body mass index; DBP, diastolic blood pressure; HADS, Hospital Anxiety and Depression Scale; HDL ‑C, high ‑density lipoprotein cholesterol, LDL ‑C, low ‑density lipoprotein cholesterol; SBP, 
systolic blood pressure; others, see TABLE 1
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in exposure to risk factors both in the hospi‑
tal and primary care patients in one setting of 
the study. Our results, although cannot be re‑
garded as a strong supportive evidence, are clear‑
ly in line with guidelines for cardiac prevention 
for clinical practice, which recommend nurse ‑led, 
simple outpatient cardiac prevention and reha‑
bilitation programs as an effective tool in pri‑
mary and secondary CVD prevention.1
In general, the assessment just after finaliz‑
ing the intervention program suggested a posi‑
tive effect on blood lipids (mainly on LDL ‑C), in‑
crease of physical activity, some favorable chang‑
es in diet and by decrease of depression and anx‑
iety. Although not every positive change persist‑
ed until 1 year after the intervention program, 
patients from the INT hospital and primary prac‑
tice remained more active, had more healthy 
diet, improved lipid profile, and in case of pri‑
mary care, had lower blood pressure as com‑
pared with UC patients. Cardiologists and pri‑
mary care physicians tend to focus on cardio‑
protective medication.16 Similar to the observa‑
tion from all sites from the EUROACTION, in 
the Polish component of the study, the effect of 
the intervention on the use of cardioprotective 
medications was modest and it seems that life‑
style changes, mainly in physical activity and 
diet, were more important.12
It is likely that favorable effect of the EURO‑
ACTION intervention persisted for longer than 
1 year and gradually deteriorated afterwards. 
Further, it is likely that the effect of decreased 
exposure to risk factors and favorable lifestyle 
on mortality persisted until the end of observa‑
tion, as observed in many prospective studies.
There is an extensive body of evidence on 
the effectiveness of nurse ‑led secondary pre‑
vention clinics. Gains were reported not only 
as a reduction of CVD risk factors but reduc‑
tion was shown for recurrent events, all ‑cause 
significant (TABLE 1). There were 61 deaths iden‑
tified in patients from the INT hospital and 92 
deaths in patients from the control hospital 
(hazard ratio [HR], 0.58; 95% CI, 0.42–0.82). 
After adjustment for sex and baseline diagno‑
sis of myocardial infarction (unequally distrib‑
uted variables), the risk of death was still low‑
er in patients from the INT hospital (HR, 0.7; 
95% CI, 0.5–0.99). Adding age to the model did 
not change the estimate but removed the sig‑
nificance (TABLE 3).
For high ‑risk patients, the average time of 
follow ‑up was slightly shorter in the UC prac‑
tice (12.1 vs 12.6 years; P = 0.01) and there were 
25 deaths identified in patients from the INT 
practice and 51 deaths in patients from the UC 
practice (HR, 0.53; 95% CI, 0.3–0.95). Adjust‑
ment for age, sex, and risk factors resulted in 
the slight change of the hazard ratio and the 
statistical significance was lost (HR, 0.66; 95% 
CI, 0.36–1.24).
For combined CHD and high‑risk patients, af‑
ter adjustment for age, sex, and history of myo‑
cardial infarction or other CHD, patients from 
the INT centers appeared to have 36% lower risk 
of death compared with UC patients (HR, 0.64; 
95% CI, 0.48–0.86) (TABLE 3).
DISCUSSION With the exception of the mul‑
tifactorial primary prevention program which 
was carried out in 1970s,14 findings from the EU‑
ROACTION remain the only evidence from Po‑
land which is based on experimental design and 
which confirm the effectiveness of the well de‑
signed and well executed cardiac prevention 
programs. Previous EUROACTION reports fo‑
cused on the effects on exposure to risk fac‑
tors and cost effectiveness.12,15 This report ex‑
pands our understanding by the observation 
of mortality reduction in relation to reduction 
TABLE 3 Risk of death in the intervention hospital and primary care practice compared with usual care centers
Hospitals Primary care Hospitals and primary care
HR 95% CI HR 95% CI HR 95% CI
Not adjusted 0.58 0.42–0.82 0.53 0.3–0.95 0.53 0.4–0.71
Adjusted for age 0.6 0.43–0.84 0.67 0.37–1.21 0.62 0.46–0.83
Adjusted for age and sex 0.67 0.48–0.93 0.65 0.36–1.18 0.64 0.48–0.86
Adjusted for sex and MI 0.7 0.5–0.99 – – 0.66 0.49–0.88
Adjusted for sex and MI or 
other CHD
– – – – 0.55 0.41–0.74
Adjusted for age, sex, and MI 0.74 0.52–1.04 – – 0.71 0.53–0.95
Adjusted for age, sex, and MI 
or other CHD
– – – – 0.64 0.48–0.86
Adjusted for age, sex, and RFs – – 0.66 0.36–1.24 – –
Abbreviations: CHD, coronary heart disease; HR, hazard ratio; MI, myocardial infarction; RFs, risk factors
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presented. The most important is that although 
the EUROACTION was designed as a cluster ran‑
domized controlled trial, a study which involves 
centers from only 1 country is observational. Re‑
cruitment on the level of hospitals and prima‑
ry practices affected negatively the comparabil‑
ity of the study samples and made the compari‑
sons vulnerable for confounding. Although we at‑
tempted to control the most important unequally 
distributed confounders (diagnosis of myocardial 
infarction and sex, major risk factors) including 
the other variables in the statistical model, even 
equally distributed in the study samples (like 
age in hospitals) could eliminate significance 
of the association with no considerable change 
of the average estimate. In the EUROACTION, 
the sample size was initially planned for the as‑
sessment of differences in the prevalence of risk 
factors between the study groups.12 The prob‑
lem of low statistical power affected both hos‑
pital and primary care part of the project, but 
it is worth noting that in both settings, the ef‑
fects of intervention on reduction in mortali‑
ty and in primary care countered the initial un‑
equal exposure to some CVD risk factors, which 
was lower in the UC practice. The second reserva‑
tion would be that the study group after 12 years 
differed from the original EUROACTION sam‑
ple by natural elimination (deaths) of persons 
at high risk, which was unequal in study groups 
(more persons died in the UC groups). It is like‑
ly that persons who died could be more exposed 
to risk factors and this could decrease the dif‑
ferences in mortality between the study groups. 
Further, the effect of intervention led by nurs‑
es is related to their expertise as well as differ‑
ences in the conditions of the patients, but also 
depends on what care is provided in the control 
patients.17 It is likely that EUROACION UC cen‑
ters were stimulated to pay more attention to 
prevention measures than average healthcare 
centers in Poland. Finally, shortly after the EU‑
ROACTION, the population of Małopolska Prov‑
ince was exposed to the population intervention, 
that is, broadcasting of the educational materi‑
als on CVD prevention in the local television.26 
and cardiovascular readmission rates, and 
the duration of hospitalization.17 However, 
some trials showed no effect of nurse ‑led care 
as compared with UC for all ‑cause mortali‑
ty.18,19 For secondary prevention, in the meta‑
‑analysis of 12 randomized clinical trials,17 out 
of which 9 reported all ‑cause mortality, most 
had short time observation (1–2 years) and 
only 2 continued observation for longer per‑
dios, that is, 4 and 10 years.20,21 Our estimate 
for HR is very close to the average of the whole 
meta ‑analysis (odds ratio, 0.78; 95% CI, 0.65–
0.95) and to the study with 10 years of observa‑
tion (odds ratio, 0.74; 95% CI, 0.55–0.98). Fur‑
ther, we have provided some information on 
the beneficial effect of primary prevention on 
mortality in primary care high ‑risk patients 
which is scarce in the literature.
Since 2012, the European guidelines for 
CVD prevention recommend the integration 
of nurse ‑coordinated prevention programs into 
healthcare systems11 and nurses together with 
general practitioners and allied health profes‑
sionals should deliver CVD prevention pro‑
grams for high ‑risk patients within the prima‑
ry care.1 In Poland, prevention was introduced 
as an important part of the work of nurses and 
nurse ‑led clinics (individual and group nurs‑
ing practices) in law over 20 years ago.22,23 How‑
ever, no CVD prevention program was target‑
ed (and funded) for nurses at the national lev‑
el. This might be a reason why the effective‑
ness of CVD prevention program supported 
by the Polish National Health Fund and tar‑
geted at general practitioners was less effec‑
tive than expected.10
In 2019, the Polish National Health Fund in‑
troduced a new nation ‑wide system of coordinat‑
ed care after myocardial infarction, which makes 
hospitals responsible for the care of the patient 
for up to 1 year after hospitalization due to myo‑
cardial infarction.24,25 The EUROACTION model 
might be ideal to ensure better outcomes at the 
most reasonable costs.
There are several important limita‑
tions for the  interpretation of the  results 
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FIGURE 1  Kaplan–Meier survival curves illustrating the risk of death for intervention (INT; A) and usual care (UC; B) centers
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It could reduce the difference in impact between 
the INT and UC centers; however, it is unlikely 
that this would have had an impact on differ‑
ences in survival.
Nevertheless, besides of being the only more 
recent, mortality‑based observation in Poland, 
which is in line with expectations from prima‑
ry and secondary CVD prevention programs, 
this study has some important strengths. First, 
hospitals served the districts which had similar 
morality from all causes and from cardiovascu‑
lar diseases (Supplementary material, Figure S1) 
and primary practices served the same commu‑
nity. Both hospitals and primary practices were 
randomly allocated to INT and UC. Second, all 
data collection was done according to the same 
protocol. Third, we were able to assess surviv‑
al status for all participants of the Polish part 
of the EUROACTION. The original EUROAC‑
TION intervention was not effective in reduc‑
ing smoking in the whole study. However, in‑
tensifying counselling and using optional var‑
enicline increased smoking abstinence and re‑
duced cardiovascular risk in the later EUROAC‑
TION Plus study.27 This all allows us to suggest 
that in Poland, the EUROACTION ‑type, nurse‑
‑managed, comprehensive education and reha‑
bilitation program has the best available evi‑
dence for its effectiveness12,15,28 and it is worth 
considering to implement it in to clinical prac‑
tice unless the evidence for more efficacious and 
cost ‑effective type of intervention appears. Fur‑
thermore, this study identified the need for re‑
peated intervention in patients with CVD and 
individuals at high risk to encourage them to 
maintain healthy lifestyle and adhere to medi‑
cation over subsequent years.
Conclusions In the  Polish component of 
the study, the effect of the EUROACTION in‑
tervention program on classic risk was consid‑
erable. Mainly, there was a strong effect on life‑
styles, that is, an increase of physical activity and 
favorable changes in diet were observed, which 
persisted at (1‑year) longitudinal observation. 
These changes could have contributed to lower 
mortality in patients from the INT centers, de‑
spite that, with the exception of more frequent 
fruit and vegetables consumption, 12‑year sur‑
vivors did not maintain favorable lifestyle char‑
acteristics and risk factors pattern. These results 
emphasize the need for sustaining the interven‑
tions to help patients maintain a healthy lifestyle.
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